Page 3 - Event Free Survival News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Elias jabbourFirst reportComparing ponatinibNewly diagnosedAcute lymphocytic leukemiaCall cancerAll leukemiaPh positiveOph allTyrosine kinase inhibitorsTki therapyCombination therapyBcr ablPonatinib dosePonatinib dosingComplete response

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Neoadjuvant durvalumabJohn heymachAdjuvant durvalumabPartnership withNon small cell lung cancerEarly stage lung cancerEarly stage nsclcDurvalumab therapyOverall survivalProgression free survivalEvent free survivalPathologic complete responsePd l1 expressionPd l1 levelAdverse eventsDrug adverse event

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHans vitzthumDevelopment agreementAstellas pharma incEpicentrx incActinium pharmaceuticals incOncology incMemorial sloan kettering cancer centerAmerican association for cancer researchNational cancer instituteLifesci advisorsAmerican associationCancer researchAbout actinium pharmaceuticalsElderly relapsedRefractory acute myeloid leukemia

Actinium Pharma (ATNM) Presents Data Demonstrating Actimab-A s Potential

Actinium Pharma (ATNM) Presents Data Demonstrating Actimab-A s Potential
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSandesh sethHans vitzthumOncology incEpicentrx incNational cancer instituteDevelopment agreementAmerican association for cancer researchLifesci advisorsAstellas pharma incActinium pharmaceuticals incMemorial sloan kettering cancer centerAmerican associationCancer researchNon small cellActinium pharmaceuticals

Immunotherapy improves lung cancer outcomes

Immunotherapy given before and after surgery significantly improved outcomes in patients with operable non-small cell lung cancer.

United statesElissa wolfsonJohn heymachUniversity of texasAmerican association for cancer researchScience advisory boardAmerican associationCancer researchLung cancerNon small cell lung cancerEsectable cancerPlatinum based chemotherapyDjuvant placeboPathologic complete responseEvent free survivalUniversity of texas md anderson cancer center